1912-42-1 Usage
Uses
Used in Pharmaceutical Industry:
1H-pyrrolo(2,3-b)pyridine-3-acetic acid is used as an anti-inflammatory and analgesic agent for the treatment of conditions such as arthritis, inflammatory bowel disease, and chronic pain. Its ability to reduce inflammation and alleviate pain makes it a potential therapeutic option for these conditions.
Used in Oncology:
1H-pyrrolo(2,3-b)pyridine-3-acetic acid is used as a potential anti-tumor agent in cancer treatment. Research suggests that it may have anti-tumor properties, making it a candidate for further investigation in the development of cancer therapies.
Used in Immunology:
1H-pyrrolo(2,3-b)pyridine-3-acetic acid is used as an immunomodulatory agent in the treatment of autoimmune diseases. Its ability to modulate the immune system suggests that it may be effective in managing conditions where the immune system is overactive or misdirected.
Overall, 1H-pyrrolo(2,3-b)pyridine-3-acetic acid shows promise as a versatile compound with a range of potential therapeutic applications across different medical fields. Further research and development are needed to fully understand its mechanisms of action and optimize its use in clinical settings.
Check Digit Verification of cas no
The CAS Registry Mumber 1912-42-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,9,1 and 2 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1912-42:
(6*1)+(5*9)+(4*1)+(3*2)+(2*4)+(1*2)=71
71 % 10 = 1
So 1912-42-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H8N2O2/c12-8(13)4-6-5-11-9-7(6)2-1-3-10-9/h1-3,5H,4H2,(H,10,11)(H,12,13)
1912-42-1Relevant academic research and scientific papers
THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE
-
Page/Page column 214-215, (2012/02/02)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.
NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION
-
Page/Page column 287, (2008/12/08)
The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus
